It is welcome news that Gail Prileszky and colleagues are addressing the evidence gap for this common condition and are looking at patient preferences in their trial. The NICE guideline's ranking of levonorgestrel-releasing intrauterine system (LNG-IUS or Mirena®) above other treatments is indeed problematic in practice, where an emphasis on choice for the fully-informed patient seems more …